Micafungin Rompharm (Micafungin)

Micafungin belongs to the echinocandin class and works by inhibiting the enzyme β‑1,3‑D‑glucan synthase. This enzyme is essential for producing β‑1,3‑D‑glucan, a key component of the fungal cell wall. Inhibiting its synthesis weakens the cell wall, leading to osmotic instability and fungal cell death.

The specific dose and duration of Micafungin Rompharm are determined by the prescribing clinician based on the patient’s condition, severity of infection, renal and hepatic function, and other individual factors. Healthcare professionals should follow local prescribing information and adjust therapy as needed.

The safety of Micafungin Rompharm in pregnancy and lactation has not been fully established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Micafungin, as an echinocandin, offers a different mechanism of action compared with azoles or polyenes. It is fungicidal against most Candida species and has a favorable safety profile, especially regarding renal toxicity. Compared with azoles, it has fewer drug‑drug interactions and is less likely to cause hepatotoxicity, though monitoring remains important.

Micafungin Rompharm should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product must be administered, allow it to reach room temperature before infusion, following aseptic technique.

Micafungin Rompharm is supplied as an intravenous solution and is administered by slow infusion into a vein, usually over 60 minutes. The infusion rate and duration are set by the prescribing clinician based on the patient’s clinical status and the specific indication.

Serious risks include severe hepatic dysfunction, anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, acute renal failure, and severe hypotension. Patients should be monitored for signs of liver injury, allergic reactions, and changes in renal function throughout therapy.

Micafungin Rompharm is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for patients with pre‑existing severe hepatic impairment, and it should be avoided in individuals where the risk of serious allergic reactions outweighs potential benefits.